The primary section III medical trial on a multivalent HFMD vaccine on this planet
BEIJING–(BUSINESS WIRE)–Sinovac Biotech Ltd. (SINOVAC or the Firm) (NASDAQ: SVA), a number one supplier of biopharmaceutical merchandise in China, at the moment kicked off the enrollment for a Section III medical trial on a vaccine candidate to stop HFMD brought on by each Enterovirus 71 (EV71) and Coxsackievirus 16 (CA16). Notably, no multivalent vaccines in opposition to HFMD have but been authorized for advertising worldwide.
The Section III medical trial is designed to be a multicenter, randomized, double-blind, managed trial to judge the efficacy, security and immunogenicity of this vaccine candidate in infants and younger kids aged 6 to 71 months.
SINOVAC has initiated a section I/II medical trial on its bivalent vaccine in China since September 2023. The outcomes from Section I/II medical trial demonstrated that the vaccine candidate has favorable security and immunogenicity.
HFMD could be brought on by a number of enteroviruses, which frequently exhibit low cross-immunogenicity, resulting in inadequate safety. HFMD primarily impacts kids below 5 years previous, accounting for not less than 90% of the whole HFMD sufferers. To reinforce safety for kids, SINOVAC is dedicated to researching and growing multivalent vaccines that deal with protections in opposition to a broader vary of dominant virus sorts. Primarily based on these efforts, the Firm has additionally developed the world’s first tetravalent enterovirus inactivated vaccine which has lately been authorized for medical trials this December. This vaccine is geared toward stopping HFMD brought on by EV71, CA16, CA10 and CA6.
Devoted to offering complete safety for kids, SINOVAC will collaborate with companions to advance medical analysis on each bivalent and tetravalent enterovirus inactivated vaccines, with the aim of creating these vaccines accessible available in the market as quickly as potential.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical firm that focuses on the R&D, manufacturing, and commercialization of biomedical merchandise that shield in opposition to human infectious ailments.
SINOVAC’s product portfolio contains vaccines in opposition to COVID-19, enterovirus 71 (EV71) contaminated hand-foot-mouth illness (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal illness, mumps, and so forth.
The COVID-19 vaccine, CoronaVac ®, has been authorized to be used in additional than 60 nations and areas worldwide. The hepatitis A vaccine, Healive ®, handed WHO prequalification necessities in 2017. The EV71 vaccine, Inlive ®, is an modern vaccine below Class 1 Preventative Organic Merchandise and commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine had been prequalified by the WHO.
SINOVAC was the primary firm to be granted approval for its H1N1 influenza vaccine Panflu.1 ®, which has provided the Chinese language authorities’s vaccination marketing campaign and stockpiling program. The Firm can also be the one provider of the H5N1 pandemic influenza vaccine, Panflu ®, to the Chinese language authorities stockpiling program.
SINOVAC regularly dedicates itself to pipeline growth together with however not restricted to new know-how, new vaccines in addition to different biomedical merchandise. We are going to consistently discover international alternatives of strategic enlargement.
For extra data, please go to the Firm’s web site at www.sinovac.com.
View supply model on businesswire.com: https://www.businesswire.com/information/house/20241216409593/en/
Sinovac Biotech Ltd.
Helen Yang
Tel: +86-10-8279 9720
E-mail: ir@sinovac.com
Supply: Sinovac Biotech Ltd.
